Drug Profile
Research programme: peptide-based immunotherapeutics - InterK Peptide Therapeutics
Alternative Names: Compound A - InterK Peptide Therapeutics; Compound B - InterK Peptide Therapeutics; Lck activators - InterK Peptide Therapeutics; Peptide based therapeutics - InterK Peptide Therapeutics; Synthetic peptide sequences - InterK Peptide Therapeutics; Synthetic peptide-based compounds - InterK Peptide TherapeuticsLatest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator InterK Peptide Therapeutics
- Class Anti-infectives; Antineoplastics; Immunotherapies; Peptides
- Mechanism of Action Immunomodulators; Lymphocyte specific protein tyrosine kinase p56(lck) stimulants; Protein kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Cancer
Most Recent Events
- 05 Sep 2023 Preclinical development is ongoing in Australia for Cancer (InterK Peptide Therapeutics website, September 2023)
- 05 Sep 2023 Preclinical trials in Autoimmune disorders in Australia (InterK Peptide Therapeutics website, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in Australia